

AI Patient Pre-Screening



Sponsor Experience

AI Patient Pre-Screening gives sponsors real-time visibility into trial-specific patient access and eligibility trends — while enabling sites to identify patients faster and enroll more efficiently. Together, this **reduces trial delays, de-risks enrollment, and drives better performance** across your portfolio.

Total patients
341,000

From EHR
323,000


Therapeutic areas



Population pyramid



Ethnicity/Race Distribution



Evidence-Backed Patient Access

Move beyond projections. Access real, verified patient data to assess trial feasibility and site fit before selection, and monitor actual enrollment capacity after.

Pre-screening activity

35 patients



Top criteria leading to ineligibility

Any other active skin disease or condition that may interfere with assessment of HS
31 patients excluded

Prescription topical therapies for the treatment of HS within 14 days prior to baseline visit
16 patients excluded

Real-Time Visibility

Gain live access to prescreening activity across your trials, from site adoption to individual eligibility bottlenecks, directly in your Sponsor Dashboard.

Accelerate enrollment and trial timelines

In minutes, sites get a redacted and assessed record ready for review. They identify and reach out to eligible patients faster, reducing trial delays on your end.

Patient Medical record

Name: [REDACTED]
Date of Birth: [REDACTED]
Age: 67 year old
Gender: Male

1. Initial Diagnosis (03/2023)
[REDACTED], a 67-year-old male, presented with abdominal pain and unintended weight loss over the past 6 months. Diagnosed with Crohn's Disease Activity Index (CDAI) of 328 indicating severe disease activity. Endoscopic findings confirmed active inflammation and ulceration, leading to the diagnosis of Crohn's disease.

2. Follow-Up Evaluation (05/2023)
A follow-up endoscopy was performed three months after diagnosis. The Simple Endoscopic Score (SES-CD) was measured at 12, indicating partial remission. Mr. Smith continues to report intermittent abdominal pain, but the frequency of diarrhea has decreased.

3. Ongoing Management (06/2023)
Mr. Smith's treatment plan includes continuing his current medication, dietary modifications and regular monitoring. Further assessments are planned to track disease progression and optimize his therapy as needed. The patient is scheduled for his next endoscopic evaluation in six months to reassess the SES-CD and adjust treatment accordingly.

PATIENT ID: ID6453

✓ ELIGIBLE

- ✓ I01 • Individuals 55 years of age or older who are at risk for a first CV event with required number of risk factors
- ✓ I03 • ≥ 250 CDAI score
- ✗ NOT ELIGIBLE
- ✗ E03 • ≥ 20 for SES-CD

Scan to learn more

